Additional Positive Efficacy Data with BI-1808 monotherapy from Ph 2a anti-TNFR2 program Announced
“We are thrilled by the observation of these partial responses in the CTCL cohort, which, together with the previously reported data, support the potential of BI-1808 to become a new class of immunomodulatory treatment option for patients with different kinds of cancers,” said Martin Welschof, Chief Executive Officer at BioInvent. “CTCL is an important indication where there is a high unmet need for new safe and effective solutions for patients, and we are now evaluating the next possible steps to accelerate the development of BI-1808 in this disease. We look forward to the emerging data from this trial from the CTCL cohorts as well as the ovarian cancer, and additional cohorts”.
Share:
More News
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.
“Many solid tumors remain difficult to treat despite advances in immunotherapy,” said Rustam Esanov, CEO and co-founder of Reprogram Biosciences. “Our approach is differentiated by its reprogramming of the tumor itself into a site of immune activation, rather than relying on exogenous immune cells or broadly acting systemic agents.”
Mabwell, an innovation-driven biopharmaceutical company with a fully integrated industry chain, today announced that the first patient has been dosed in a Phase III clinical trial evaluating its novel Nectin-4-targeting ADC (Bulumtatug Fuvedotin, or BFv, R&D code: 9MW2821) for the treatment of locally advanced or metastatic triple-negative breast cancer (TNBC).